Výsledky vyhledávání - "Hong-Keng Liew"

Akademický článek

Spontaneous Regression of Plasmablastic Lymphoma in an Immunocompetent Patient: Case Report and Review of the Literature

Autor: Kee Tat Lee, Nurul Akmar Misron, Norasmidar Abdul Aziz, Chin Hau Wong, Hong Keng Liew

Publikováno v: Case Reports in Hematology, Vol 2022 (2022)

Plasmablastic lymphoma (PBL) is a rare and highly aggressive type of lymphoma, which is commonly associated with human immunodeficiency virus (HIV) infection. Spontaneous regression of aggressive lymphomas is rare as they typically require administra

Externí odkaz: https://doaj.org/article/1cfa80cbbdf44e759fd8eceb3e72230a

Zobrazit plný text záznamu

Plný text ve formátu HTML

A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia

BACKGROUND Patients with transfusion-dependent ?-thalassemia need regular red-cell transfusions. Luspatercept, a recombinant fusion protein that binds to select transforming growth factor ? superfamily ligands, may enhance erythroid maturation and re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4fe5db0b5c20202be3afeae19191200
http://hdl.handle.net/11591/430144

Zobrazit plný text záznamu

Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with β-Thalassemia in the Believe Trial

Autor: George Zhang, Vip Viprakasit, Silverio Perrotta, Jay Backstrom, Ali T. Taher, Ersi Voskaridou, Hong Keng Liew, Olivier Hermine, Yu Tian, Derek Tang, Dimana Miteva, Abderrahim Khelif, John B. Porter, Antonis Kattamis, Maria Domenica Cappellini, Ashutosh Lal, Thomas D. Coates, Jeevan K. Shetty, Tatiana Zinger

Publikováno v: Blood. 136:47-48

Introduction: Regular red blood cell (RBC) transfusions are the main supportive treatment for chronic anemia due to β-thalassemia. Transfusion-dependent pts require ICT to prevent iron overload from RBC transfusions, and associated complications. Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8ac1b0f5a67f6adb3f23bbe5c97a556d
https://doi.org/10.1182/blood-2020-136517

Zobrazit plný text záznamu

A randomized double blind control trial comparing filgrastim and pegfilgrastim in cyclophosphamide peripheral blood hematopoietic stem cell mobilization

Autor: Xavier Yoon Han Sim, See-Guan Toh, Sen-Mui Tan, Jerome Tsen-Chuen Tan, Pek-Kuen Liew, Su-Hong Lim, Ahlam-Naila Kori, Jay-Suria Rajasuriarr, Kian-Meng Chang, Shu-Ping Wong, Yong-Khee Guan, Anselm-Ting Su, Yuin-Yin Cheng, Tee-Chuan Ong, Hong-Keng Liew, Jew Win Kuan

Publikováno v: Transfusion and Apheresis Science. 53:196-204

There are few randomized trials comparing filgrastim and pegfilgrastim in peripheral blood stem cell mobilization (PBSCM). None of the trials studied the effects of the timing of pegfilgrastim administration on the outcomes of mobilization. We conduc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c3ffea58ca1f83b7b2937ed2d1fe582
https://doi.org/10.1016/j.transci.2015.03.017

Zobrazit plný text záznamu

Evaluating Luspatercept Responders in the Phase 3, Randomized, Double-Blind, Placebo-Controlled BELIEVE Trial of Luspatercept in Adult Beta-Thalassemia Patients (Pts) Who Require Regular Red Blood Cell (RBC) Transfusions

Publikováno v: Blood. 134:3545-3545

Introduction: β-thalassemia is an inherited hemoglobinopathy characterized by ineffective erythropoiesis and anemia. Luspatercept is a first-in-class erythroid maturation agent that binds to select TGF-β superfamily ligands to reduce aberrant Smad2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9987a606607845a58311aa538f360a34
https://doi.org/10.1182/blood-2019-122685

Zobrazit plný text záznamu

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

Autor: Olivier Hermine, Ersi Voskaridou, Wen-Ling Kuo, Thomas D. Coates, Dimana Miteva, Jeevan K. Shetty, Ali T. Taher, Silverio Perrotta, Tatiana Zinger, Hong Keng Liew, Antonis Kattamis, Maria Domenica Cappellini, John B. Porter, Vip Viprakasit, Peter G. Linde, Abderrahim Khelif, Abderrahmane Laadem, Daniel Sinsimer

Publikováno v: Blood. 134:2245-2245

Introduction: BELIEVE is an ongoing phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of luspatercept, a first-in-class erythroid maturation agent, in adults with β-thalassemia requiring regular RBC trans

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ef5e1a480340a187e1719f5606275396
https://doi.org/10.1182/blood-2019-122561

Zobrazit plný text záznamu

The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions

Publikováno v: Blood. 132:163-163

Introduction: β-thalassemia is an inherited hemoglobinopathy associated with an erythroid maturation defect characterized by ineffective erythropoiesis and impaired RBC maturation. Luspatercept is a first-in-class erythroid maturation agent under de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::56c04f6d9a9bedbd4b2671d44fc6f4b8
https://doi.org/10.1182/blood-2018-163

Zobrazit plný text záznamu

Akademický článek

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.

Autor: Cappellini, M. Domenica¹ maria.cappellini@unimi.it, Vip Viprakasit², Taher, Ali T.³, Georgiev, Pencho⁴, Kuo, Kevin H. M.⁵, Coates, Thomas⁶, Voskaridou, Ersi⁷, Hong-Keng Liew⁸, Pazgal-Kobrowski, Idit⁹, Forni, G. L.¹⁰, Perrotta, Silverio¹¹, Khelif, Abderrahim¹², Lal, Ashutosh¹³, Kattamis, Antonis¹⁴, Vlachaki, Efthymia¹⁵, Origa, Raffaella¹⁶, Aydinok, Yesim¹⁷, Bejaoui, Mohamed¹⁸, Ho, P. Joy¹⁹, Lee-Ping Chew²⁰

Publikováno v: New England Journal of Medicine. 3/26/2020, Vol. 382 Issue 13, p1219-1231. 13p.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání